AbbVie (ABBV) Change in Accured Expenses (2012 - 2026)

AbbVie (ABBV) has reported Change in Accured Expenses for 15 consecutive years, with $1.2 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Change in Accured Expenses rose 133.4% year-over-year to $1.2 billion in Q2 2026; TTM through Jun 2026 was $740.0 million, a 44.49% decrease from a year earlier, with the FY2025 full-year figure at $951.0 million, up 437.29% from the prior year.
• Change in Accured Expenses was $1.2 billion for Q2 2026 at AbbVie, up from -$1.6 billion in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $2.5 billion in Q3 2023 and troughed at -$1.7 billion in Q2 2024.
• A 5-year average of $352.5 million and a median of $314.5 million in 2024 frame the typical range for Change in Accured Expenses.
• Across the five-year window, Change in Accured Expenses slumped 363.89% in 2022 and surged 928.42% in 2023, its largest moves.
• Over 5 years, Change in Accured Expenses stood at $1.3 billion in 2022, then plunged by 85.99% to $179.0 million in 2023, then surged by 596.65% to $1.2 billion in 2024, then slumped by 147.96% to -$598.0 million in 2025, then jumped by 301.0% to $1.2 billion in 2026.
• The last three Change in Accured Expenses figures came in at $1.2 billion (Q2 2026), -$1.6 billion (Q1 2026), and -$598.0 million (Q4 2025), per Business Quant data.